Sateesh K. Nagumantry

Peterborough, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 22, 2025

A Case of Metastatic Spinal Cord Compression in a Patient With Coexisting Chronic Lymphocytic Leukemia and Colon Cancer.

A Case of Metastatic Spinal Cord Compression in a Patient With Coexisting Chronic Lymphocytic Leukemia and Colon Cancer.

Journal: Cureus

Published: November 27, 2025

First cases of danicopan use in adolescent patients with paroxysmal nocturnal haemoglobinuria.

First cases of danicopan use in adolescent patients with paroxysmal nocturnal haemoglobinuria.

Journal: British journal of haematology

Published: December 17, 2024

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experience.

Oral iptacopan for paroxysmal nocturnal haemoglobinuria-First real-world experience.

Journal: British journal of haematology

Published: November 12, 2024

The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.

The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.

Journal: The Lancet. Oncology

Published: July 18, 2024

Falsely low glycosylated haemoglobin levels probably secondary to hypersplenism in a patient with diabetes mellitus.

Falsely low glycosylated haemoglobin levels probably secondary to hypersplenism in a patient with diabetes mellitus.

Journal: BMJ case reports

Published: April 04, 2024

Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.

Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.

Journal: American journal of hematology

Published: December 04, 2023

CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.

CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.

Journal: British journal of haematology

Published: November 10, 2023

Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.

Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.

Journal: Leukemia

Published: September 26, 2023

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria.

Journal: Blood

Published: July 07, 2023

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Journal: Blood

Published: June 20, 2023

Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria.

Experience of compassionate-use pegcetacoplan for paroxysmal nocturnal hemoglobinuria.

Journal: Blood

Published: May 31, 2022

Showing 1-12 of 14

Last Updated: 09/26/2026